SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors anticipate upcoming earnings and potential hyperscaler announcements, crucial for the company's AI infrastructure growth. Community discussions revolve around the timing of a new lease and the impact of Macquarie's recent funding draw. Bullish sentiment remains high due to the expected increase in AI data center demand and APLD's strategic position.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a strategic partnership to develop 'Made in US' post-quantum cryptography solutions for US government and defense, sparking bullish sentiment. The community is actively discussing the potential for a short squeeze and significant upside, drawing comparisons to other quantum stocks. With high trading volume and positive news, investors are optimistic about the company's future growth and potential double-digit price targets.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to a significant surge fueled by new AI partnerships with industry leaders like OpenAI, Google, NVIDIA, and Snowflake. The community is buzzing about the company's shift towards agentic automation and its potential to become a central player in enterprise AI, drawing comparisons to Palantir ($PLTR). Many believe $PATH has been undervalued and are anticipating further gains, citing its strong cash position and strategic partnerships as catalysts for future growth.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending as investors discuss a potential short squeeze, fueled by its high short interest and growing optimism around its transition to AI and high-performance computing. Community members are pointing to the stock's setup mirroring past breakouts, while also highlighting analyst price targets and the increasing open interest in call options. Some are closely watching for news regarding the Lake Cayuga site approval, which could act as a further catalyst.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach multi-decade highs, sparking discussions about a potential breakout. Community members are debating whether demand is crushing short positions and anticipating further gains, with some pointing to a possible short squeeze. The broader context involves rising interest in precious metals as a hedge against economic uncertainty, amplified by a potentially weaker dollar and a possible government shutdown.

TOSHI

TOSHI is trending as the community rallies behind the token, pointing to strong chart patterns and increasing volume. Many are drawing comparisons to previous meme coin surges, speculating on potential listings on major exchanges like Robinhood and Binance. The community emphasizes its strong organic growth and active engagement.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending amid discussions about defense spending, potential contract wins, and comparisons to other high-growth tech and defense companies. The community is actively debating its valuation, potential for acquisitions, and upcoming catalysts like government contracts and drone technology advancements. Some traders are taking profits after a significant run-up, while others see it as a long-term growth play.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending amid increased Bitcoin production and expansion into AI cloud services, sparking community excitement around its potential in both sectors. Some investors are drawing comparisons to IREN, while others highlight HIVE's strong assets and growing hashrate, anticipating further upward momentum. Discussions also focus on potential partnerships and undervaluation relative to peers.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending as investors discuss its growth potential in the autonomous delivery market, especially following recent acquisitions and partnerships with major platforms like DoorDash and Uber Eats. Community members are weighing the stock's valuation and future prospects, noting the high short interest and potential for a squeeze. Bullish sentiment is fueled by expectations of revenue growth and expansion into new markets, although some caution against potential pullbacks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors actively discuss the potential impact of data center constraints and new partnerships on the company's growth. Community members are speculating about upcoming news and potential deals, particularly related to its stake in Clickhouse and its role in AI infrastructure. The stock's volatility and potential for significant gains are also prominent talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIRA Pharmaceuticals Inc saw its shares rise to the highest levels in nearly two months after the clinical-stage pharmaceutical company announced the board’s approval of its planned acquisition of SKNY Pharmaceuticals Inc, a deal valued at over $60 million.The acquisition, which still requires approval from MIRA and SKNY’s shareholders, has been valued based on third-party analysis conducted by Moore Financial Consulting.&nbsp;SKNY Pharmaceuticals has an enterprise value of approximately $30.5 million, while MIRA's value stands at $30 million, bringing the combined enterprise value to over $60 million.Shares of MIRA Pharmaceuticals have gained 8.7% year-to-date, closing at $1.25 on Thursday, before dipping 6.4% in after-hours trading.MIRA CEO Erez Aminov emphasized that the merger combines two robust pipelines and a unified strategy, with a focus on developing therapies for obesity and nicotine dependence.&nbsp;Under the terms of the merger, SKNY is required to hold at least $5 million in cash or other assets to be transferred at closing.&nbsp;MIRA is preparing to file with the U.S. Securities and Exchange Commission to seek shareholder approval for the deal.SKNY Pharmaceuticals’ lead compound, SKNY-1, is being developed as a next-generation oral therapeutic targeting CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B), which plays a key role in dopamine metabolism and addiction regulation.&nbsp;The compound is being evaluated for its potential to address both metabolic dysfunction and nicotine dependence, with applications in two high-value therapeutic areas.MIRA’s leadership views the addition of SKNY-1 to its pipeline as a key step in positioning the company to capitalize on these growing markets. Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, Itzchak Angel, said the pharmacological profile of SKNY-1 could make it an effective treatment for both addiction and metabolic disorders.&nbsp;Early data from the compound’s development has been promising, according to Angel.On Stocktwits, sentiment was described as 'bullish' amid a 1,350% surge in 24-hour message volume.&nbsp;One user noted that the merger would be a significant win, expressing confidence that shareholders from both companies would approve, while another shared frustration over a pre-market entry at $1.70, followed by an immediate pullback.<stembedurl>https://stocktwits.com/BearTamerTrading/message/613998754</stembedurl><stembedurl>https://stocktwits.com/Kc24mo/message/613981879</stembedurl>The stock has risen 8.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong

Retail sentiment on Stocktwits surged, with users expressing optimism about the merger’s success, despite a pullback in after-hours trading.

Equity

Shares of Mira Pharmaceuticals&nbsp;gained over 19% on Wednesday, marking their best session in over a month, after the company's oral ketamine analog showed promising data in a preclinical study.Mira said its Ketamir-2 therapy significantly reduced pain symptoms in rats, with some test animals returning to pre-diabetic sensitivity levels.The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects, the company added.On Stocktwits, the news sent 24-hour message volume involving Mira soaring 8,500% by late Wednesday — the highest among all healthcare stocks — with sentiment turning even more 'extremely bullish.'<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MIRA_sentiment_and_message_volume_as_of_April_16_png_9320cb3838.webp" alt="MIRA sentiment and message volume as of April 16.png" width="1318" height="316"><figcaption>MIRA sentiment and message volume as of April 16. | source: Stocktwits</figcaption></figure>One watcher expects the stock to cross the $1.2 mark on Thursday easily.<stembedurl>https://stocktwits.com/BadBritt/message/611883890</stembedurl>Another said a new 52-week high was imminent.<stembedurl>https://stocktwits.com/HMIC/message/611835137</stembedurl>Mira has already begun dosing and testing Ketamir-2 in a Phase I trial in Israel, which is expected to be completed in the fourth quarter of 2025.&nbsp;A Phase IIa trial in diabetic neuropathy is set to begin by the end of 2025, with efficacy data anticipated in early 2026.&nbsp;Mira is also developing a topical formulation for localized pain and exploring Ketamir-2's potential in PTSD treatment.Separately, Mira is progressing with its acquisition of SKNY Pharmaceuticals and sees promise in SKNY-1, a next-generation oral therapy targeting obesity and smoking cessation.Mira Pharmaceuticals' stock has lost over 8% this year but has risen nearly 29% over the past 12 months.Shares of the company fell over 11% after-hours on Wednesday, likely due to profit-taking.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial

The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects. 

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data

MIRA Pharmaceuticals stock surged on Thursday following new preclinical data on Ketamir-2, MIRA's novel oral ketamine analog, highlighting its unique selectivity and favorable safety profile for...

Small-cap biotech Mira Pharmaceuticals (MIRA) has experienced a meteoric rise and subsequent plunge, captivating retail investors in the process.The company's stock surged a staggering 627% on Monday following promising preclinical data for its novel oral ketamine analog, Ketamir-2. This dramatic increase sparked a frenzy of interest, with the number of Stocktwits followers surging over 212% in just one week.Ketamir-2 has shown potential as a treatment for neurological and neuropsychiatric disorders, according to media <a href="https://www.benzinga.com/news/24/07/39885749/nano-cap-mira-pharmaceuticals-oral-ketamine-analog-shows-potential-in-neuropsychiatric-disorders?utm_source=TechInvestorNews&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_content=site">reports</a>. Unlike traditional ketamine, it exhibits better oral bioavailability and appears to have a reduced risk of side effects. These advantages could position Mira as a significant player in the development of novel therapies.The company is also preparing to submit an Investigational New Drug (IND) application to the FDA by the end of this year.However, the euphoria was short-lived. The stock plummeted over 54% on Tuesday, prompting some to take profits while they still had them.Although some investors believe this represents a buying opportunity, others remain cautious, citing the long road to commercialization and the potential for future volatility.The Stocktwits stream had plenty of bearish posts, like the one from “<a href="https://stocktwits.com/Wolf_Of_Penny_Stocks/message/580409064">Wolf_of_penny_stocks</a>”, advising investors to “scalp and run” as Monday’s stock move was a “pump on preclinical data… even if they are successful it will take another 8-10 years before they generate any revenue.”<figure class="image"><img style="aspect-ratio:1320/450;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Stocktwits_user_comment_on_MIRA_stream_Jul_23_1a46479621.png" alt="Stocktwits user comment on MIRA stream Jul 23.png" width="1320" height="450"><figcaption>Stocktwits user comment on MIRA stream Jul 23</figcaption></figure>The rapid rise and fall of Mira Pharmaceuticals highlights the speculative nature of the biotech sector. While preclinical data is undoubtedly encouraging, investors must approach such volatile stocks with caution and conduct thorough due diligence before making investment decisions, as many posts on MIRA’s Stocktwits stream suggest. &nbsp;

Why Small-Cap Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's Mira Pharma stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2.

Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2. However, a subsequent freefall has left investors wondering if this was a flash in the pan or the start of something bigger.

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders

MIRA Pharmaceuticals reveals preclinical data for its novel oral ketamine analog, Ketamir-2, targeting neurological and neuropsychiatric disorders. With superior oral absorption and efficacy...

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety...

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year Mira Pharmaceuticals Announces...

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel...

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Mira Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$1.33
Prev Close	$1.32
Open	$1.32
Dividend Yield	0.00%
50-Day Moving Average	$1.41
Beta	0.00
Avg. Volume	856,589.38
PE Ratio	-2.75

52-Week High	$2.56
52-Week Low	$0.73
Market Capitalization	$25.17M
EPS (Annual)	-$0.5085
Price to Book	40.27
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MIRA
Mira Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MIRA News

MIRA Mira Pharmaceuticals Inc